Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 8Mycosis Fungoides 3Lymphoma, T-Cell, Peripheral 3Recurrence 2Lymphoma, T-Cell, Cutaneous 2Sezary Syndrome 1Mesothelioma, Malignant 1Lymphomatoid Papulosis 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Brentuximab Vedotin × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡